Last reviewed · How we verify
insulin lispro LM
insulin lispro LM is a Premixed insulin Small molecule drug developed by Eli Lilly and Company. It is currently FDA-approved for Type 1 diabetes mellitus, Type 2 diabetes mellitus. Also known as: Low Mix, Humalog.
Insulin lispro LM is a premixed insulin formulation that combines rapid-acting insulin lispro with intermediate-acting insulin to provide both mealtime and basal glucose control.
Insulin lispro LM is a premixed insulin formulation that combines rapid-acting insulin lispro with intermediate-acting insulin to provide both mealtime and basal glucose control. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | insulin lispro LM |
|---|---|
| Also known as | Low Mix, Humalog |
| Sponsor | Eli Lilly and Company |
| Drug class | Premixed insulin |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin lispro LM (also known as Humalog Mix) is a fixed-ratio mixture of insulin lispro (a rapid-acting insulin analog) and insulin lispro protamine suspension (intermediate-acting). The rapid-acting component addresses postprandial (after-meal) blood glucose spikes, while the intermediate-acting component provides basal insulin coverage between meals and overnight. This dual-action formulation simplifies insulin therapy by combining two insulin types in a single injection.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies (PHASE4)
- The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV) (PHASE4)
- Lispro Mid Mixture (MM) Intensive Mixture Therapy With Progressive Dose-Titration of Lispro Low Mixture (LM) or Biphasic Insulin Aspart 30/70 (S019) (PHASE4)
- A Study for Patients With Diabetes Mellitus (IOPA) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- insulin lispro LM CI brief — competitive landscape report
- insulin lispro LM updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI
Frequently asked questions about insulin lispro LM
What is insulin lispro LM?
How does insulin lispro LM work?
What is insulin lispro LM used for?
Who makes insulin lispro LM?
Is insulin lispro LM also known as anything else?
What drug class is insulin lispro LM in?
What development phase is insulin lispro LM in?
What are the side effects of insulin lispro LM?
What does insulin lispro LM target?
Related
- Drug class: All Premixed insulin drugs
- Target: All drugs targeting Insulin receptor
- Manufacturer: Eli Lilly and Company — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 1 diabetes mellitus
- Indication: Drugs for Type 2 diabetes mellitus
- Also known as: Low Mix, Humalog
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing